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ABBREVIATIONS 36 
 37 
ACTH, Adrenocorticotrophic hormone 38 
AII, Angiotensin II 39 
AT1, Angiotensin II type 1 receptor 40 
ACE, Angiotensin converting enzyme 41 
CRH, Corticotrophin releasing hormone 42 
GH, Growth hormone 43 
GR, Glucocorticoid receptor 44 
HPA, hypothalamic-pituitary-adrenal axis  45 
11β-HSD, 11β-hydroxysteroid dehydrogenase type 1 or 2  46 
IGF, Insulin-like growth factor –I or –II 47 
MR, Mineralocorticoid receptor 48 
PG, Prostaglandin E2 or F2α 49 
PGDH, 15-hydroxy prostaglandin dehydrogenase 50 
PGHS. Prostaglandin H2 synthase 51 
PNMT, Phenylethanolamine-N-methyl-transferse 52 
POMC, Pro-opiomelanocorticotrophin 53 
T4, Thyroxine 54 
T3, Tri-iodothyronine 55 
UCP, Uncoupling protein 56 
 57 
 58 
NEW FINDINGS 59 
 60 
What is the topic of this review? 61 
 62 
 This review discusses the role of the glucocorticoids as regulatory signals during intrauterine 63 
development. 64 
 65 
 It examines the functional significance of these hormones as maturation, environmental and 66 
programming signals in determining offspring phenotype. 67 
 68 
What advances does it highlight?  69 
 70 
 It focuses on the extensive nature of the regulatory actions of these hormones  71 
 It highlights the emerging data that these actions are mediated, in part, by the placenta, 72 
other endocrine systems and epigenetic modifications of the genome.  73 
 74 
 75 
 76 
 77 
 78 
 79 
 80 
 81 
 82 
 83 
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ABSTRACT 84 
 85 
Glucocorticoids are important regulatory signals during intrauterine development. They act as 86 
maturational, environmental and programming signals that modify the developing phenotype to 87 
optimise offspring viability and fitness.  They affect development of a wide range of fetal tissues by 88 
inducing changes in cellular expression of structural, transport and signalling proteins, which have 89 
widespread functional consequences at the whole organ and systems levels. Glucocorticoids, 90 
therefore, activate many of the physiological systems that have little function in utero but are vital at 91 
birth to replace the respiratory, nutritive and excretory functions previously carried out by the 92 
placenta. However, by switching tissues from accretion to differentiation, early glucocorticoid 93 
overexposure in response to adverse conditions can program fetal development with longer term 94 
physiological consequences for the adult offspring which can extend to the next generation.  The 95 
developmental effects of the glucocorticoids can be direct on fetal tissues with glucocorticoid 96 
receptors or mediated by changes in placental function or other endocrine systems. At the 97 
molecular level, glucocorticoids can act directly on gene transcription via their receptors or indirectly 98 
by epigenetic modifications of the genome. This review examines the role and functional significance 99 
of glucocorticoids as regulatory signals during intrauterine development and discusses the 100 
mechanisms by which they act in utero to alter the developing epigenome and ensuing phenotype. 101 
 102 
 103 
INTRODUCTION  104 
 105 
In adults, glucocorticoids are stress hormones with a wide range of physiological effects which aid 106 
survival in environmental conditions that challenge homeostasis. They maintain blood flow and a 107 
supply of nutrients and oxygen to tissues when these resources are either scarce or in increased 108 
demand. In the fetus, glucocorticoids have an even broader range of functions during normal and 109 
adverse conditions (Fowden et al., 1998).   Towards term, they act as the primary maturational signal 110 
in the developmental sequence that prepares the fetus for the new challenges of extra-uterine life. 111 
Earlier in gestation, they can act as environmental cues that alter fetal development in relation to 112 
resource availability for intrauterine growth (Fowden & Forhead, 2009). This improves viability both 113 
before and at birth, particularly when conditions are sub-optimal for survival.  However, by changing 114 
fetal tissue development, early exposure to excess glucocorticoids modifies the phenotype with life-115 
long physiological consequences (Fowden et al., 1998; 2006; Harris & Seckl, 2011; Moisiadis & 116 
Matthews, 2014). Glucocorticoids are, therefore, also programming signals that adapt intrauterine 117 
development to optimise offspring fitness (Fowden & Moore, 2012). This review examines the role 118 
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and functional significance of glucocorticoids as regulatory signals during intrauterine development 119 
and discusses the mechanisms by which they act in utero. 120 
 121 
GLUCOCORTICOID BIOAVAILABILITY DURING DEVELOPMENT  122 
Glucocorticoids are present in both the maternal and fetal circulation and increase in concentration 123 
towards term in most species, even in normal conditions (Fowden & Forhead, 2009).  Generally, 124 
concentrations are higher in the mother than fetus so maternal glucocorticoids enter the placenta 125 
and fetus down their concentration gradient for most of gestation.  In sheep and mice, for example, 126 
70-80% of the glucocorticoid in the fetal circulation is of maternal origin when the fetal adrenal 127 
cortex is relatively inactive or incapable of steroidogenesis (Hennessy et al. 1982; Huang et al., 128 
2011).  Consequently, environmental stressors that raise maternal glucocorticoids levels also 129 
increase feto-placental glucocorticoid exposure (Fowden & Forhead, 2009). Once the fetal 130 
hypothalamic-pituitary-adrenal (HPA) axis is activated in late gestation, feto-placental glucocorticoid 131 
exposure can be increased independently of the mother by elevating glucocorticoid secretion from 132 
the fetal adrenal cortex. This occurs towards term as part of the normal maturational process and 133 
earlier in gestation in response to circadian cues and environmental stressors like fetal 134 
hypoglycaemia and hypoxaemia (Fowden et al.., 1998).  In fetal mice, the adrenal cortices are 135 
sufficiently active in late gestation to supply glucocorticoids to the mother as significant amounts of 136 
corticosterone are detected in the circulation of adrenalectomised dams (Cottrell et al., 2011).  137 
Glucocorticoids can, therefore, cross the placenta in both directions depending on the concentration 138 
gradient. Finally, at the tissue level, glucocorticoid bioavailability can be altered independently of 139 
maternal or fetal glucocorticoid concentrations by changes in tissue 11β-hydroxysteroid 140 
dehydrogenase (11β-HSD) activity (Chapman et al., 2013).  This enzyme exists in two isoforms; 11β-141 
HSD1 which predominantly regenerates active glucocorticoids from their inactive metabolites and is 142 
expressed in a wide range of fetal tissues and 11β-HSD2, which converts active glucocorticoids to 143 
their inactive forms and is high in activity in the placenta and fetal kidney (Chapman et al., 2013). In 144 
addition, P-glycoprotein, a member of the ABCB family of multidrug resistance transporters, is 145 
expressed in the placenta and fetal brain where it transports glucocorticoids out of the cells (Pappas 146 
et al., 2014).  Placental P-glycoprotein and 11β-HSD2, therefore, act as barriers to placental 147 
glucocorticoid transfer and normally limit fetal exposure to the higher maternal glucocorticoid 148 
concentrations. However, in several species, placental expression of these two proteins declines 149 
towards term and during adverse conditions earlier in gestation (Fowden & Forhead, 2004; Kalabis 150 
et al., 2005; Mark et al., 2009). This will further increase placental glucocorticoid exposure alongside 151 
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the concomitant increases in fetal and maternal glucocorticoid concentrations with consequences 152 
for placental gene expression and transport phenotype.  In addition, ontogenic and environmentally  153 
induced changes in the activity of the two isoforms in fetal tissues exert fine control over 154 
glucocorticoid bioavailability locally in a tissue specific fashion (Fowden et al., 2008; Harris & Seckl, 155 
2011; Chapman et al., 2013) Ultimately, the actions of the glucocorticoids are controlled by the 156 
glucocorticoid (GR) and mineralocorticoid receptors (MR), which change in abundance 157 
developmentally and in response to environmental cues in a tissue specific manner (Brown et al., 158 
1996; Speirs et al., 2004; Cuffe et al., 2012).  159 
 160 
Clinically, synthetic glucocorticoids are given to pregnant women to treat asthma, arthritis and 161 
adrenal insufficiency, and to improve neonatal viability in threatened preterm delivery (McKinlay et 162 
al., 2014). These drugs are also given to mares to treat laminitis and to cattle to induce delivery at or 163 
near term (Johnson et al., 2002; Mansell et al., 2006). Synthetic glucocorticoids are up to 20 times 164 
more potent than their natural counterparts and are poorly inactivated by 11β-HSD2 (Chapman et 165 
al., 2013). They also bind predominantly to GR whereas natural glucocorticoids bind to both GR and 166 
MR. Clinical and experimental treatment with synthetic glucocorticoids, therefore, also alters fetal 167 
growth and development but the specific effects, mechanisms of action and long term outcomes of 168 
this treatment often differ from those seen in response to natural glucocorticoids (Jellyman et al., 169 
2015).  170 
 171 
DEVELOPMENTAL EFFECTS OF THE GLUCOCORTICOIDS 172 
Glucocorticoids have a wide range of developmental effects in normal and adverse conditions, 173 
particularly in tissues essential for survival immediately at birth (Figure 1).  They induce changes in 174 
tissue expression of cytostructural proteins, receptors, transporters, ion channels and enzymes 175 
(Fowden & Forhead, 2004; 2009). These changes lead to alterations in the morphology, metabolism, 176 
hormone sensitivity and biochemical composition of fetal tissues with widespread functional 177 
consequences at the whole organ and systems levels (Fowden et al., 2006; Harris & Seckl, 2011; 178 
Moisiadis & Matthews, 2014; Rog-Zielinska et al., 2014). Glucocorticoids, therefore, activate many of 179 
the physiological processes that have little or no function in utero but which are vital to extra-uterine 180 
life, such as pulmonary gas exchange, hepatic gluconeogenesis, gastrointestinal digestion and 181 
thermogenesis (Figure 1).  For instance, the effects of cortisol in increasing hepatic glycogen 182 
deposition, glucogneogenic enzyme activity and adrenoreceptor abundance mean that the neonatal 183 
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liver can produce glucose endogenously in response to hypoglycaemia and other stresses (Fowden 184 
et al., 1998; 2006). However, by stimulating differentiation, glucocorticoids limit the degree of 185 
further cell proliferation in many fetal tissues.  For example in fetal sheep, maturational 186 
concentrations of cortisol stimulate terminal differentiation of proliferative mono-nucleated 187 
cardiomyocytes to their binucleated form that can still hypertrophy but not divide (Thornburg et al., 188 
2011).  Certainly, in sheep, the prepartum cortisol surge decreases the fetal growth rate overall in 189 
parallel with the maturation of individual fetal tissues (Fowden et al., 1996). In addition to visceral 190 
tissues essential for neonatal survival, glucocorticoids also affect growth and development of tissues 191 
like the brain, heart and skeletal muscle that are important to offspring viability and fitness in the 192 
longer term (Champagne et al., 2006; Brown, 2014; Rog-Zielinska et al., 2014). In the fetal heart, 193 
both basal glucocorticoid concentrations and preterm cortisol infusion have been shown to increase 194 
cardiac weight relative to body weight during late gestation (Rog-Zielinska et al., 2014). At 195 
maturational cortisol concentrations, this cardiac growth is believed to reflect the concomitant 196 
hypertension but infusion of cortisol at subpressor doses directly into the coronary vessels 197 
stimulates cardiomyocyte expression of proliferative markers in association with increased cardiac 198 
weight in fetal sheep during late gestation (Giraud et al., 2006). Thus, in some fetal tissues, 199 
glucocorticoids appear to stimulate cell proliferation while also activating the cellular pathways 200 
which eventually switch the cell cycle to differentiation, perhaps at a critical concentration or 201 
duration of increased exposure.  202 
 203 
Early overexposure to glucocorticoids in response to environmental insults appears to induce this 204 
switch from tissue accretion to differentiation prematurely in several fetal tissues.  While this has 205 
beneficial effects on neonatal viability if pre-term delivery occurs, it reduces fetal growth overall and 206 
decreases total cell numbers in certain tissues (Fowden et al., 1996; 1998).  These effects of early 207 
glucocorticoid overexposure are tissue specific and dose dependent. They are also influenced by 208 
gestational age at the time of overexposure.  For instance, increasing fetal cortisol levels to 209 
prepartum values enhances activity of most of the key rate limiting enzymes in the hepatic 210 
gluconeogenic pathway at 130 days but not at 115 days (Fowden & Forhead, 2009).  Similarly, the 211 
fetal cardiac and pulmonary transcriptomes induced by early glucocorticoid exposure are distinct 212 
from those seen at term (McGillick et al., 2013; Richards et al., 2014). The effects of early 213 
glucocorticoid exposure, therefore, do not recapitulate entirely the maturational effects of the 214 
prepartum cortisol surge.   215 
 216 
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By altering fetal growth and development, early exposure to natural or synthetic glucocorticoids has 217 
long term effects on the physiological phenotype of the offspring.  The changes in tissue structure 218 
and function induced in utero may persist throughout life or emerge at natural transitions in the life 219 
course such as birth, puberty or pregnancy (Wada, 2008).  Alternatively, they may become apparent 220 
only after postnatal environmental challenges such as undernutrition and hypoxia (Daskalakis et al., 221 
2013).  In experimental animals, prenatal glucocorticoid overexposure by fetal or maternal 222 
administration affects the same range of tissues and cellular processes in adulthood as seen 223 
prenatally (Harris & Seckl, 2011; Moisiadis & Matthews, 2014; Rog-Zielinska et al., 2014). This leads 224 
to adult dysfunction of multiple physiological systems including the cardiovascular, metabolic, 225 
endocrine and nervous systems as well as organs not functional in utero like the reproductive tract 226 
(Fowden et al., 2006; Harris & Seckl, 2011). There are also changes in adult behaviour, memory and 227 
appetite regulation after prenatal glucocorticoid exposure in rodents (Huang, 2011; Bouret et al., 228 
2015).   These adult phenotypic changes tend to be more pronounced with prenatal overexposure to 229 
synthetic than natural glucocorticoids and become more obvious with advancing age, possibly due to 230 
the reduced functional reserve capacity of adult tissues prematurely switched from accretion to 231 
differentiation in utero by glucocorticoid overexposure (Somm et al., 2012; Jellyman et al., 2015). 232 
 233 
Early glucocorticoid exposure in utero affects at least two generations. In rodents, guinea pigs and 234 
sheep, the adult F1 metabolic and endocrine phenotype induced by F0 maternal glucocorticoid 235 
administration has been shown to be inherited to the F2 generation without further intervention 236 
(Drake et al., 2005; Iqbal et al., 2012; Long et al., 2013a&b).  In rodents, these intergenerational 237 
effects are transmitted through both the maternal and paternal line, which may reflect physiological 238 
changes in the pregnant F1 mother and/or a germ line epigenetic component (Drake et al., 2005). 239 
However, the effects of F0 glucocorticoid treatment do not persist to the F3 generation never 240 
exposed to glucocorticoid excess, which indicates that any glucocorticoid-induced epigenetic marks 241 
are not stably inherited (Drake et al., 2005).  In humans, prenatal treatment with synthetic 242 
glucocorticoids also alters blood pressure and indices of insulin resistance postnatally but the adult 243 
physiological outcomes of early life glucocorticoid overexposure in humans appear to be less 244 
pronounced than in experimental animals and, to date, have unknown intergenerational 245 
consequences (Harris & Seckl 2011; McKinlay et al., 2014).  This relates to the longer human lifespan 246 
as the majority of infants clinically exposed to synthetic glucocorticoids in utero are still relatively 247 
young adults.  The outcomes of clinical glucocorticoid treatment of pregnant women for their infants 248 
are also likely to depend on the type and dose of synthetic glucocorticoid given, its route of 249 
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administration and on the timing and duration of treatment during pregnancy (Brownfoot et al., 250 
2013; Aiken et al., 2014; Romeijko-Wolniewicz et al., 2014).  251 
 252 
 253 
MECHANISMS OF ACTION 254 
The glucocorticoids can regulate intrauterine development via a wide range of different mechanisms 255 
from the systems to the gene level.  Their actions may be direct or mediated indirectly via changes in 256 
placental function or production of other growth regulatory hormones and growth factors (Vaughan 257 
et al., 2011; Fowden & Forhead, 2014).  Together these actions alter the availability of substrates for 258 
intrauterine growth, their metabolic fate and the expression of many nutrient and hormone 259 
sensitive genes that control intrauterine development.   260 
 261 
Placental effects 262 
Maternal glucocorticoids administration during late gestation reduces placental weight in all species 263 
studied to date (Vaughan et al., 2011). In sheep, fetal or maternal glucocorticoid treatment also 264 
alters the gross placentome morphology in association with reduced expression of proliferative 265 
markers and increased expression of apoptotic factors (Ward et al., 2002; Braun et al., 2015). In 266 
rodents, maternal administration of natural or synthetic glucocorticoids leads to reduced vessel 267 
volumes and/or surface area in the placenta, which decreases the potential for transplacental 268 
transfer of substances via simple and facilitated diffusion as well as by active transport (Vaughan et 269 
al., 2012; 2013; O’Connell et al., 2013).  In several species, direct measurements of placental 270 
nutrient transport have shown that raising fetal or maternal glucocorticoid concentration reduces 271 
placental transfer of glucose and amino acids during treatment (Vaughan et al., 2011; 2012; 2015a; 272 
Audette et al., 2014). These changes are often accompanied by alterations in expression of the 273 
respective transporters and in nutrient consumption by the placenta (Fowden et al., 2015).  274 
Increased glucocorticoid exposure of the placenta from either the maternal or fetal circulation also 275 
alters its expression of Vegf, 11β-HSD2, the renin-angiotensin system and a range of other genes 276 
involved in its endocrine function (Fowden et al., 2008; 2015).  In rodents and humans, there is also 277 
evidence for sexual dimorphism in these placental responses (Stark et al., 2011; Cuffe et al., 2011; 278 
2012). Glucocorticoids can, therefore, induce alterations in placental morphological, transport and 279 
metabolic phenotype that contribute to the fetal growth restriction observed when glucocorticoid 280 
concentrations are raised.  Moreover, the intergenerational effects of the glucocorticoids may also 281 
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involve modification of the placental transport phenotype as amino acid transport and transporter 282 
expression are altered in the F2 placenta of F0 dexamethasone treated rodent dams (Drake et al., 283 
2011; Vaughan et al., 2015b).  284 
 285 
Effects on other endocrine systems 286 
Glucocorticoids affect the development and function of many other endocrine systems in the fetus 287 
and placenta, particularly during late gestation (Fowden & Forhead, 2004; Fowden et al., 2015). In 288 
the placenta, they affect production of sex steroids, eicosanoids, lactogenic hormones and 289 
adipokines (Table 1).  In the fetus, they affect almost all of the endocrine systems functional during 290 
late gestation including the HPA axis itself (Table 1).  Even in endocrine systems like the endocrine 291 
pancreas where there is little direct experimental evidence for maturational effects of 292 
glucocorticoids, there are ontogenic changes in fetal β cell function that parallel the prepartum 293 
cortisol increment (Aldoretta et al., 1998; Fowden et al., 2004).  In contrast, in rodents, 294 
glucocorticoids are essential for normal development of the pancreatic β cells before the 295 
maturational increase in their concentration towards term (Gesina et al., 2006; Blondeau et al., 296 
2012).  297 
 298 
Glucocorticoids can act either directly via altered transcription of hormone genes or indirectly via 299 
the enzymes involved in hormone synthesis and metabolism (Table 1).  They also alter expression of 300 
several growth factors and hormone receptors in feto-placental tissues including the insulin like 301 
growth factors (IGFs), growth hormone (GH) receptor, adrenoreceptors, angiotensin (AII) receptors, 302 
MR and GR themselves (Table 1) . In addition, they can affect components of the intracellular 303 
signalling pathways for hormones and growth factors and, hence, have local tissue effects 304 
independent of the circulating concentrations.  For example, glucocorticoids affect the abundance of 305 
several proteins in the insulin signalling pathway in fetal skeletal muscle near term although not 306 
expression of the insulin receptor itself (Jellyman et al., 2012; Blanco et al., 2014). Maturationally, 307 
these effects of the glucocorticoids enable the sensitivity of the endocrine axes to be set 308 
appropriately for extrauterine life and, in some species, also ensure that fetal maturation is co-309 
ordinated with the onset of parturition.   310 
 311 
The glucocorticoid-induced changes in fetal endocrine function lead to prepartum increases in the 312 
fetal concentration of several other hormones including T3, IGF-I, leptin and adrenaline, which, in 313 
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turn, have independent effects on fetal tissue growth and function (Fowden & Forhead, 2009). 314 
Indeed, the increases in plasma T3 and leptin and the decreases in tissue IGF-II abundance may 315 
mediate, in part, the maturational effects of the prepartum cortisol surge. Thyroid hormones, in 316 
particular, have been shown to be essential for aspects of glucocorticoid-stimulated maturation of 317 
the renin-AII system, the somatotrophic axis, hepatic glucogenic capacity, lung liquid reabsorption 318 
and terminal differentiation of the cardiac myocytes in fetal sheep during late gestation (Fowden & 319 
Forhead, 2014).  Similarly, leptin appears to have an important role in modifying the actions of 320 
cortisol on gluconeogenic enzyme activities in ovine fetal liver near term (Forhead et al., 2008).  It 321 
may also be involved in the developmental changes in cardiac function and hypothalamic appetite 322 
regulatory circuits during the perinatal period (Vickers & Sloboda, 2012; Bouret et al., 2015). Indeed, 323 
ontogenic and environmentally induced changes in the circulating concentration and tissue receptor 324 
abundance of these hormones may explain, in part, the gestational dependence of some of the 325 
developmental outcomes associated with raised glucocorticoid levels in utero.  326 
 327 
During adverse conditions earlier in gestation, the glucocorticoid-induced endocrine changes have 328 
immediate benefits to fetal survival by maintaining pregnancy and modifying fetal growth to match 329 
the more limited supply of oxygen and nutrients.  Development of certain fetal tissues like the brain 330 
are preserved in these circumstances at the expense of others such as the liver and skeletal muscle.  331 
However, if the endocrine changes persist after restoration of normal conditions, they may become 332 
more detrimental to intrauterine development and compromise the ability of the fetus to respond 333 
to subsequent environmental challenges. For example, fetal HPA responses to stressful stimuli such 334 
as hypoxia are known to be altered by prior exposure to glucocorticoids (Fletcher et al., 2003; 335 
Jellyman et al., 2004). Similarly, early activation of the switch in the somatotrophic axis from local 336 
GH independent IGF-I synthesis to GH dependent hepatic production of endocrine IGF-I is likely to 337 
affect growth of many fetal tissues long after normal fetal glucocorticoid levels are restored.  Indeed, 338 
changes in endocrine function induced by early glucocorticoid exposure in utero are known to 339 
persist after birth to alter the adult endocrine environment (Moisiadis & Matthews, 2014).  For 340 
instance, prenatal glucocorticoid exposure alters adult HPA function at every level of the axis from 341 
the brain to tissue glucocorticoid bioavailability (Jellyman et al., 2015). In turn, these programmed 342 
changes in HPA function may contribute to the adult cardiometabolic dysfunction associated with 343 
prenatal glucocorticoid overexposure.  The regulatory effects of glucocorticoids on intrauterine 344 
development, therefore, involve multiple interactions between different endocrine systems, when 345 
glucocorticoids are acting both as maturational and environmental signals.  346 
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 347 
Epigenetic effects 348 
At the molecular level, glucocorticoids act via several different mechanisms to alter gene expression. 349 
Bound to their receptors they act as enhancer binding proteins that activate or repress gene 350 
expression via interaction with glucocorticoid response elements (GRE) in promotor or other 351 
regulatory regions of the genome (Adcock et al., 2004).  For example, cortisol-stimulated down-352 
regulation of IGF2 gene transcription in ovine fetal liver is mediated preferentially by a GRE in the 5’ 353 
regulatory region of the untranslated leader exon 7 containing the P4 promotor (Li et al., 1998). In 354 
contrast, cortisol-induced up-regulation of IGF1 gene transcription in fetal liver is likely to be more 355 
indirect as there are no GREs in the vicinity of the promotor regions of this gene (Fowden et al., 356 
2011).  Postnatally, glucocorticoids are also known to alter gene expression more indirectly via 357 
epigenetic modifications of the genome and chromatin structure (Weaver, 2009). These include DNA 358 
methylation, histone modifications and changes in abundance of non-coding long and microRNAs 359 
(Adcock et al., 2004; Weaver, 2009).  However, relatively little is known about the epigenetic effects 360 
of glucocorticoids in utero.  361 
 362 
Glucocorticoids have been shown to alter GRE methylation of the tyrosine aminotransferase gene in 363 
fetal rat hepatocytes treated in vitro (Thomassin et al., 2001). They also affect methylation of the 364 
differentially methylated region (DMR) and the imprinted control region (ICR) of the Igf2 gene in 365 
fetal liver of the F1 and F2 generation, respectively, of F0 rat dams dexamethasone exposed during 366 
late pregnancy (Drake et al., 2011). In guinea pigs, maternal betamethasone treatment changes 367 
global methylation of the placenta, liver, kidney and adrenal gland of fetuses delivered 1 and 14 days 368 
after ending treatment (Crudo et al., 2012). This treatment also alters DNA methylation and histone 369 
h3 lysine 9 acetylation in the fetal hippocampus (Crudo et al., 2013b). The glucocorticoid-induced 370 
methylomes are tissue specific and change with time after treatment (Crudo et al., 2012). In the 371 
placenta and fetal kidney, the epigenetic changes were accompanied by altered expression of DNA 372 
methyltransferase 1 and 3b involved in maintenance and de novo DNA methylation, respectively 373 
(Crudo et al., 2012). Changes in global methylation were also seen in adult tissues of the F1 and F2 374 
offspring of betamethasone treated pregnant guinea pigs, although the methylation patterns differ 375 
from those seen prenatally (Crudo et al., 2012).  More specifically, demethylation of the GR 376 
promotor and increased GR gene expression are seen in kidneys of adult rats dexamethasone 377 
overexposed during late gestation (Wyrwoll et al., 2007).  Betamethasone treatment of guinea pigs 378 
in late pregnancy also causes differential GR binding to a large number of different gene promotors 379 
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and methylation of specific GREs in the fetal hippocampal MR gene (Crudo et al., 2013a).  Taken 380 
together, these studies indicate that glucocorticoids alter DNA methylation through a range of 381 
different mechanisms from alterations in chromatin structure and global methylation pathways to 382 
more specific changes in the methylation state of CpG islands and individual CpG dinucleotides 383 
within promotors or other more distant regulatory regions of the genes (Grange et al., 2001; Zhang 384 
et al., 2013).  385 
 386 
Glucocorticoids may also act by changing the imprint status of growth regulatory imprinted genes 387 
like IGF2, which are expressed from only one allele in a parent of origin manner. In both human and 388 
ovine liver, the IGF2 gene switches from solely paternal to biallelic expression in parallel with the 389 
prepartum cortisol surge (Fowden et al., 2011).  Whether these changes in IGF2 expression are due 390 
to altered expression of the H19 derived non-coding RNA or to changes in methylation at the DMR 391 
and/or ICR of the IGF2-H19 locus remains unknown. Nor it is clear whether any of the epigenetic 392 
effects are due directly to the glucocorticoids or mediated indirectly by changes in placental function 393 
or other hormone concentrations.  Certainly, maternal treatment with synthetic glucocorticoids in 394 
rats alters placental transfer of methyl donors essential for DNA methylation (Wyrwoll et al., 2012).  395 
In addition, T3 is a key component of the epigenetic mechanism regulating GR promotor methylation 396 
in the rat brain in response to neonatal stresses (Zhang et al., 2013).  Glucocorticoid exposure in 397 
early life, therefore, affects the developing epigenome through a number of different routes with 398 
dynamic consequences for epigenetic marks throughout the lifespan of the offspring.  Indeed, the 399 
long term outcomes of prenatal glucocorticoid overexposure are likely to be modified continually by 400 
postnatal factors, often independent of the physical environment, like the level of maternal care and 401 
the reproductive history of the mother reflected in the quality and glucocorticoid content of the milk 402 
during lactation (Zhang et al., 2006; Hinde et al., 2015).  403 
 404 
CONCLUSIONS 405 
Glucocorticoids act as maturational, environmental and programming signals in regulating 406 
intrauterine development (Figure 2).  Towards term, they activate the physiological systems that 407 
replace the respiratory, nutritive and excretory functions of the placenta immediately at birth. 408 
Earlier in gestation, they act as environmental signals that modify the fetal epigenome and optimise 409 
the phenotype for the prevailing conditions in utero. At the tissue level, these maturational and 410 
developmental effects are achieved largely by switching tissues from accretion to differentiation 411 
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(Figure 2).  When this glucocorticoid-triggered switch is activated prematurely, there can be 412 
permanent changes in cell type, tissue morphology and organ function that have long term 413 
physiological consequences for the offspring, particularly as it ages.  If the postnatal environment 414 
differs from that signalled in utero, the glucocorticoid-induced changes in offspring phenotype may 415 
become maladaptive and lead to accelerated ageing with early onset of degenerative 416 
cardiometabolic diseases characteristic of old age (Figure 2).  Nevertheless, the developmental 417 
adaptations induced in utero by glucocorticoids maximise the chances of survival to reproductive age 418 
and, hence, transmission of genes onto the next generation. However, the molecular mechanisms 419 
involved in these processes remain largely unknown. Nor is it clear to what extent the regulatory 420 
actions of the glucocorticoids are sex-linked or modifiable by postnatal interventions when 421 
outcomes are likely to be detrimental to adult health.   422 
 423 
 424 
FIGURE LEGENDS 425 
Figure 1: Schematic diagram of the developmental effects of the glucocorticoids on visceral tissues 426 
of fetal sheep during late gestation. Data from Fowden & Forhead, 1998; 2004; 2009; 2014 and 427 
Fowden et al., 1998; 2015. 428 
Figure 2: Schematic diagram of the regulatory roles of glucocorticoids during intrauterine 429 
development and their functional significance for offspring fitness in pre- and post-natal life.  430 
 431 
 432 
 433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
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Table 1: Endocrine systems affected by maternal and/or fetal glucocorticoids in sheep and rodents 
Endocrine system Hormones Processes involved Tissue 
    
Sex steroids Progesterone Cytochrome P45017α Placenta 
 Estrogens C17-20 lyase, Aromatase  
    
Eicosanoids PGE2, PGF2α PGHS, PGDH Placenta 
    
Lactogenic hormones Placental 
lactogen 
Hormone mRNA Placenta 
 Prolactins Hormone mRNA  
    
Adipokines Leptin Hormone mRNA/protein Plasma, Placenta, Adipose 
tissue 
    
HPA axis CRH Hormone mRNA Hypothalamus 
 ACTH/POMC Prohormone convertases Pituitary 
 Glucocorticoids ACTH receptors, Cytochrome 
P45017α 
11βHSD1, 11βHSD2, GR 
Adrenal cortex  
Placenta, Brain, Peripheral 
tissues 
    
Renin- Angiotensin  
System 
Angiotensin II  Renin protein 
Angiotensinogen protein 
Angiotensin converting enzyme  
AT1 receptors mRNA 
Plasma 
Liver, Plasma 
Lungs 
Kidney 
    
Catecholamines Adrenaline Phenylethanolamine N-methyl-
transferase 
Adrenoreceptors 
Adrenal medulla 
Liver, Heart 
    
Somatotrophic axis GH 
IGF-I 
IGF-II 
GH receptor mRNA 
Peptide mRNA 
Peptide mRNA 
Liver 
Liver , Skeletal muscle 
Liver , Skeletal muscle 
    
Thyroid Hormone axis T4, T3 Deiodinase D1, D2, D3 Placenta, Liver 
Data from Fowden & Forhead, 2004; 2009; 2014; Fowden et al., 2015; Jellyman et al., 2015 724 
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